A bill to require the Secretary of Health and Human Services to make determinations of the exclusivity periods for which licensed biological products are eligible.

This legislation proposes to require the Secretary of Health and Human Services to make formal determinations regarding the exclusivity periods for licensed biological products. Biological products, or biologics, are complex medications made from living organisms. Currently, these products are granted a period of market exclusivity during which cheaper, biosimilar versions cannot be sold. This bill aims to bring more clarity to that process by requiring the government to specify exactly how long those protections last for each product. If enacted, this bill could provide more transparency for pharmaceutical companies and the public regarding when lower-cost alternatives to expensive biological drugs might become available. By establishing clear timelines for market exclusivity, the bill seeks to streamline the regulatory environment for life-saving medications and potentially influence the timing of competition in the drug market.